Abstract:e23123 Background: Pleural carcinosis caused by tumors of the chest (e.g., lung and breast cancer) or elsewhere in the body (e.g., ovarian carcinoma) that metastasize to the visceral and/or parietal pleura. Recurrent malignant pleural effusion due to pleural carcinosis is one of the most common findings in oncology. The aim of the study was to identify a miRNA signature associated with clinicians’ prescription of patients with MPE. Methods: We used qRT-PCR assay to evaluate a wide range miRNAs (1920 miRNAs) signature measured from pleural effusion between patients with cancer and healthy controls. From the data of our previous studies we selected a panel of 96 miRNAs related to malignant pleural effusion. Data were compared by three classification methods software for statistics and modeling. We used a first set of 77 pleural effusion samples as training group, including 27 patients affected by Lung Adenocarcinomas (LAC), 9 with other lung cancer, 17 with other tumors and 24 inflammatory patients as negative controls. Moreover, we used more 64 pleural effusion samples for double-blind predictive study. Data analysis was performed using a machine learning approach of a Support Vector Machine classifier with a Student's t-test feature selection procedure. Results: We identified a panel of ten miRNAs with optimum classification performance. The combination of these 10-miRNAs alone could discriminate MPE cases from negative controls with an AUC of 0.969 (accuracy = 93.5%; specificity = 91.7%). The selected panel of another 10-miRNAs could separate lung cancer cases from negative controls with an AUC of 0.973 (accuracy = 94.8%; specificity = 95.8%), and a small panel of 4-miRNAs could good discriminate LAC cases from negative controls with an AUC of 0.946 (accuracy 88.9%; specificity = 100%). The accuracy rate of the double-blind predictive sensitivity value was 90.9% and specificity value was 95.8% for MPE patients with lung cancer of miRNA signature. Conclusions: Our miRNAs profile may serve as a new biomarker for MPE diagnosis. Otherwise, we identified a 10-miRNAs signature for MPE patients with lung cancer and a 4-miRNAs for MPE patients with lung adenocarcinoma.

Diagnostic Value of Reverse-Transcriptase Polymerase Chain Reaction for MAGE Families Expression in Malignant Thoracic Pleural Effusions

Mrna Expression of MAGE Genes in Benign and Malignant Pleural Effusion

Differential Proteome Profiling of Pleural Effusions from Lung Cancer and Benign Inflammatory Disease Patients

The expression levels of VEGF and ICAM-1 in pleural effusion

Genome-wide Microrna Expression Profiling in Malignant Pleural Effusion to Identify a Ten-Microrna Signature.

The Diagnostic Significance of the Detection of Cytokeratin 19 Mrna by Quantitative RT-PCR in Benign and Malignant Pleural Effusions

Combined Detection of Carcinoembryonic Antigen and C-reactive Protein in Identifying Benign and Malignant Pleural Effusion

Diagnostic Accuracy of Cancer in Pleural Effusion: A Combination Serum Tumor Markers and Cytology

Treg/Th17 imbalance in malignant pleural effusion partially predicts poor prognosis.

The Diagnostic Value of MCP-1 and RANTES in Tuberculosis and Malignant Pleural Effusion

[Mrna Expressions of MAGE Genes in Human Lung Cancer].

Evaluation of MAGE-1 and MAGE-3 As Tumour-Specific Markers to Detect Blood Dissemination of Hepatocellular Carcinoma Cells.

Diagnostic Accuracy of Tumour Markers for Malignant Pleural Effusion: a Meta-Analysis

Diagnostic sensitivity of pleural fluid cytology in malignant pleural effusions: systematic review and meta-analysis

Detection of Telomerase Activity in Pleural Effusion Cells from Patients with Malignant Neoplasm

Application value of combined detection of exfoliative cytology,DNA heteroploid analysis and serum tumor marker in malignant pleural/ascitic fluid

Use of tumor markers in distinguishing lung adenocarcinoma-associated malignant pleural effusion from tuberculous pleural effusion

Detection of Cell-Free BIRC5 Mrna in Effusions and Its Potential Diagnostic Value for Differentiating Malignant and Benign Effusions.

Pleural fluid analysis of lung cancer vs benign inflammatory disease patients

Different expression of FoxM1 in human benign and malignant pleural effusion

Malignant Pleural Effusion Supernatants Are Substitutes for Metastatic Pleural Tumor Tissues in EGFR Mutation Test in Patients with Advanced Lung Adenocarcinoma.